9lione Raises ¥120 Million in Series A Funding
9lione, a company known for its innovative approach to pharmaceutical distribution, has successfully raised ¥120 million in a Series A funding round. The round was led by Yokohama Capital, marking a significant milestone for 9lione as it continues to enhance its pharmaceutical management solutions.
9lione offers a platform that allows users to manage pharmaceuticals using cloud technology. By simply taking pictures of prescriptions with an iPad or smartphone, users can create automatic inventory lists on the cloud. This service is available with zero initial costs and can be subscribed to in just one minute, eliminating the need for traditional Excel management.
Use of Funds
The newly acquired funds will be directed towards expanding 9lione's logistics and sales infrastructure. The company plans to develop new products aimed at medical institutions that include features like inventory visualization and transaction automation powered by AI. Additionally, there will be a focus on strengthening recruitment in various sectors such as pharmaceuticals, product management, engineering, and corporate functions. The company is also working on AI-driven demand forecasting to ensure a stable supply of pharmaceuticals at fair prices.
With the pharmaceutical market facing challenges related to surplus management and drug shortages, 9lione's solutions aim to alleviate these issues by reducing the inventory burden on medical institutions. By acting as a wholesaler with its own inventory, the company ensures compliance with GDP standards and maintains a robust system for tracking distribution history.
About 9lione
9lione operates the "9lione Cloud" and "9lione Platform," which facilitate the distribution of surplus pharmaceuticals from one medical institution or pharmacy to another. The platform is designed to help reduce surplus drugs in-house and procure hard-to-obtain pharmaceuticals, thus playing a crucial role in the efficient management of pharmaceutical supplies.